Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 29
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

  • Fernández-Santiago, Ruben
  • Merkel, Angelika
  • Castellano, Giancarlo
  • Heath, Simon
  • Raya Chamorro, Ángel
  • Tolosa, Eduard
  • Martí, Maria José
  • Consiglio, Antonella
  • Ezquerra, Mario
Background: Parkinson’s disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues., This work was supported by the Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III (ISCIII) to M.E. (grant # PI14/00426), the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) to the Movement Disorders Unit of the Neurology Service from the Hospital Clínic de Barcelona to E.T., M.-J.M., R.F.-S., and M.E. (grant # PRI-16-2017). R.F.S. was supported by a Jóvenes Investigadores grant (#SAF2015-73508-JIN) through the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (Plan Estatal de I+D+I 2013–2016) of the Spanish Ministry of Economy and Competitiveness (MINECO), and the Agencia Estatal de Investigación (AEI), which is cofunded by FEDER (AEI/FEDER/UE). Other funding included the grants BFU2013-49157-P, BFU2016-80870-P, and the European Research Council (ERC) 2012-StG (311736- PD-HUMMODEL) to A.C; ISCIII/FEDER (RD16/0011/0024) and Generalitat de Catalunya (iPS4BioMed SGR 2017–2019) to A.R.; and ISCIII/FEDER (PIE14/00061) to A.R.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

iPS cell cultures from a Gerstmann-Straussler-Scheinker patient with the Y218N PRNP mutation recapitulate tau pathology

  • Matamoros i Anglès, Andreu
  • Mayela Gayosso, Lucia
  • Richaud-Patin, Yvonne
  • Domenico, Angelique Di
  • Vergara Paños, Cristina
  • Hervera Abad, Arnau
  • Sousa, Amaia
  • Fernández Borges, Natalia
  • Consiglio, Antonella
  • Gavín Marín, Rosalina
  • López de Maturana, Rakel
  • Ferrer, Isidro (Ferrer Abizanda)
  • López de Munain, Adolfo
  • Raya Chamorro, Ángel
  • Castilla, Joaquín
  • Sanchez-Pernaute, Rosario
  • Río Fernández, José Antonio del
Gerstmann-Straussler-Scheinker (GSS) syndrome is a fatal autosomal dominant neurodegenerative prionopathy clinically characterized by ataxia, spastic paraparesis, extrapyramidal signs and dementia. In some GSS familiar cases carrying point mutations in the PRNP gene, patients also showed comorbid tauopathy leading to mixed pathologies. In this study we developed an induced pluripotent stem (iPS) cell model derived from fibroblasts of a GSS patient harboring the Y218N PRNP mutation, as well as an age-matched healthy control. This particular PRNP mutation is unique with very few described cases. One of the cases presented neurofibrillary degeneration with relevant Tau hyperphosphorylation. Y218N iPS-derived cultures showed relevant astrogliosis, increased phospho-Tau, altered microtubule-associated transport and cell death. However, they failed to generate proteinase K-resistant prion. In this study we set out to test, for the first time, whether iPS cell-derived neurons could be used to investigate the appearance of disease-related phenotypes (i.e, tauopathy) identified in the GSS patient.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Long-term labeling of hippocampal neural stem cells by a lentiviral vector

  • Suh, Hoonkyo
  • Zhou, Qi-Gang
  • Fernandez-Carasa, Irene
  • Clemenson Jr., Gregory D.
  • Pons-Espinal, Meritxell
  • Jeoung Ro, Eun
  • Marti, Mercè
  • Raya Chamorro, Ángel
  • Gage, Fred H.
  • Consiglio, Antonella
Using a lentivirus-mediated labeling method, we investigated whether the adult hippocampus retains long-lasting, self-renewing neural stem cells (NSCs). We first showed that a single injection of a lentiviral vector expressing a green fluorescent protein (LV PGK-GFP) into the subgranular zone (SGZ) of the adult hippocampus enabled an efficient, robust, and long-term marking of self-renewing NSCs and their progeny. Interestingly, a subset of labeled cells showed the ability to proliferate multiple times and give rise to Sox2+ cells, clearly suggesting the ability of NSCs to self-renew for an extensive period of time (up to 6 months). In addition, using GFP+ cells isolated from the SGZ of mice that received a LV PGK-GFP injection 3 months earlier, we demonstrated that some GFP+ cells displayed the essential properties of NSCs, such as self-renewal and multipotency. Furthermore, we investigated the plasticity of NSCs in a perforant path transection, which has been shown to induce astrocyte formation in the molecular layer of the hippocampus. Our lentivirus (LV)-mediated labeling study revealed that hippocampal NSCs are not responsible for the burst of astrocyte formation, suggesting that signals released from the injured perforant path did not influence NSC fate determination. Therefore, our studies showed that a gene delivery system using LVs is a unique method to be used for understanding the complex nature of NSCs and may have translational impact in gene therapy by efficiently targeting NSCs.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons

  • Calatayud Aristoy, Carles
  • Carola, Giulia
  • Fernandez-Carasa, Irene
  • Valtorta, Marco
  • Jiménez-Delgado, Senda
  • Díaz, Mònica
  • Soriano i Fradera, Jordi
  • Cappelletti, Graziella
  • García-Sancho, Javier
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
Patient-specific induced pluripotent stem cells (iPSCs) are a powerful tool to investigate the molecular mechanisms underlying Parkinson's disease (PD), and might provide novel platforms for systematic drug screening. Several strategies have been developed to generate iPSC-derived tyrosine hydroxylase (TH)-positive dopaminergic neurons (DAn), the clinically relevant cell type in PD; however, they often result in mixed neuronal cultures containing only a small proportion of TH-positive DAn. To overcome this limitation, we used CRISPR/Cas9-based editing to generate a human iPSC line expressing a fluorescent protein (mOrange) knocked-in at the last exon of the TH locus. After differentiation of the TH-mOrange reporter iPSC line, we confirmed that mOrange expression faithfully mimicked endogenous TH expression in iPSC-derived DAn. We also employed calcium imaging techniques to determine the intrinsic functional differences between dopaminergic and non-dopaminergic ventral midbrain neurons. Crucially, the brightness of mOrange allowed direct visualization of TH-expressing cells in heterogeneous cultures, and enabled us to isolate live mOrange-positive cells through fluorescence-activated cell sorting, for further differentiation. This technique, coupled to refined imaging and data processing tools, could advance the investigation of PD pathogenesis and might offer a platform to test potential new therapeutics for PD and other neurodegenerative diseases.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells

  • Pons-Espinal, Meritxell
  • Blasco Agell, Lucas
  • Consiglio, Antonella
Parkinson's disease (PD) is an incurable age-linked neurodegenerative disease with characteristic movement impairments that are caused by the progressive loss of dopamine-containing neurons (DAn) within the substantia nigra pars compacta. It has been suggested that misfolded protein aggregates together with neuroinfammation and glial reactivity, may impact nerve cell function, leading to neurodegeneration and diseases, such as PD. However, not many studies have been able to examine the role of human glial cells in the pathogenesis of PD. With the advent of induced pluripotent stem cell (iPSC) technology, it is now possible to reprogram human somatic cells to pluripotency and to generate viable human patient-specifc DA neurons and glial cells, providing a tremendous opportunity for dissecting cellular and molecular pathological mechanisms occurring at early stages of PD. This reviews will report on recent work using human iPSC and 3D brain organoid models showing that iPSC technology can be used to recapitulate PD-relevant disease-associated phenotypes, including protein aggregation, cell death or loss of neurite complexity and defcient autophagic vacuoles clearance and focus on the recent co-culture systems that are revealing new insights into the complex interactions that occur between diferent brain cell types during neurodegeneration. Consequently, such advances are the key to improve our understanding of PD pathology and generate potential targets for new therapies aimed at curing PD patients.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons

  • Ferrer Lorente, Raquel
  • Lozano Cruz, Tania
  • Fernández Carasa, Irene
  • Miłowska, Katarzyna
  • Mata, Francisco Javier de la
  • Bryszewska, Maria
  • Consiglio, Antonella
  • Ortega, Paula
  • Gómez, Rafael
  • Raya Chamorro, Ángel
Accumulation of misfolded α-synuclein (α-syn) is a hallmark of Parkinson's disease (PD) thought to play important roles in the pathophysiology of the disease. Dendritic systems, able to modulate the folding of proteins, have emerged as promising new therapeutic strategies for PD treatment. Dendrimers have been shown to be effective at inhibiting α-syn aggregation in cell-free systems and in cell lines. Here, we set out to investigate the effects of dendrimers on endogenous α-syn accumulation in disease-relevant cell types from PD patients. For this purpose, we chose cationic carbosilane dendrimers of bow-tie topology based on their performance at inhibiting α-syn aggregation in vitro. Dopamine neurons were differentiated from induced pluripotent stem cell (iPSC) lines generated from PD patients carrying the LRRK2G2019S mutation, which reportedly display abnormal accumulation of α-syn, and from healthy individuals as controls. Treatment of PD dopamine neurons with non-cytotoxic concentrations of dendrimers was effective at preventing abnormal accumulation and aggregation of α-syn. Our results in a genuinely human experimental model of PD highlight the therapeutic potential of dendritic systems and open the way to developing safe and efficient therapies for delaying or even halting PD progression.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

  • Fernández Santiago, Rubén
  • Merkel, Angelika
  • Castellano, Giancarlo
  • Heath, Simon
  • Raya Chamorro, Ángel
  • Tolosa, Eduardo
  • Martí Domènech, Ma. Josep
  • Consiglio, Antonella
  • Ezquerra Trabalón, Mario
Background: Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neural cells

  • Bayó Puxan, Neus
  • Terrasso, Ana Paula
  • Creyssels, Sophie
  • Simão, Daniel
  • Begon Pescia, Christina
  • Lavigne, Marina
  • Salinas, Sara
  • Bernex, Florence
  • Bosch, Assumpció
  • Kalatzis, Vasiliki
  • Levade, Thierry
  • Cuervo, Ana María
  • Lory, Philippe
  • Consiglio, Antonella
  • Brito, Catarina
Mucopolysaccharidosis type VII (MPS VII) is a lysosomal storage disease caused by deficient β-glucuronidase (β-gluc) activity. Significantly reduced β-gluc activity leads to accumulation of glycosaminoglycans (GAGs) in many tissues, including the brain. Numerous combinations of mutations in GUSB (the gene that codes for β-gluc) cause a range of neurological features that make disease prognosis and treatment challenging. Currently, there is little understanding of the molecular basis for MPS VII brain anomalies. To identify a neuronal phenotype that could be used to complement genetic analyses, we generated two iPSC clones derived from skin fibroblasts of an MPS VII patient. We found that MPS VII neurons exhibited reduced β-gluc activity and showed previously established disease-associated phenotypes, including GAGs accumulation, expanded endocytic compartments, accumulation of lipofuscin granules, more autophagosomes, and altered lysosome function. Addition of recombinant β-gluc to MPS VII neurons, which mimics enzyme replacement therapy, restored disease-associated phenotypes to levels similar to the healthy control. MPS VII neural cells cultured as 3D neurospheroids showed upregulated GFAP gene expression, which was associated with astrocyte reactivity, and downregulation of GABAergic neuron markers. Spontaneous calcium imaging analysis of MPS VII neurospheroids showed reduced neuronal activity and altered network connectivity in patient-derived neurospheroids compared to a healthy control. These results demonstrate the interplay between reduced β-gluc activity, GAG accumulation and alterations in neuronal activity, and provide a human experimental model for elucidating the bases of MPS VII-associated cognitive defects.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease

  • Domenico, Angelique Di
  • Carola, Giulia
  • Calatayud Aristoy, Carles
  • Pons-Espinal, Meritxell
  • Muñoz, Juan Pablo
  • Richaud-Patin, Yvonne
  • Fernandez-Carasa, Irene
  • Gut, Marta
  • Faella, Armida
  • Parameswaran, Janani
  • Soriano i Fradera, Jordi
  • Ferrer, Isidro (Ferrer Abizanda)
  • Tolosa, Eduardo
  • Zorzano Olarte, Antonio
  • Cuervo, Ana Maria
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
Parkinson's disease (PD) is associated with the degeneration of ventral midbrain dopaminergic neurons (vmDAns) and the accumulation of toxic α-synuclein. A non-cell-autonomous contribution, in particular of astrocytes, during PD pathogenesis has been suggested by observational studies, but remains to be experimentally tested. Here, we generated induced pluripotent stem cell-derived astrocytes and neurons from familial mutant LRRK2 G2019S PD patients and healthy individuals. Upon co-culture on top of PD astrocytes, control vmDAns displayed morphological signs of neurodegeneration and abnormal, astrocyte-derived α-synuclein accumulation. Conversely, control astrocytes partially prevented the appearance of disease-related phenotypes in PD vmDAns. We additionally identified dysfunctional chaperone-mediated autophagy (CMA), impaired macroautophagy, and progressive α-synuclein accumulation in PD astrocytes. Finally, chemical enhancement of CMA protected PD astrocytes and vmDAns via the clearance of α-synuclein accumulation. Our findings unveil a crucial non-cell-autonomous contribution of astrocytes during PD pathogenesis, and open the path to exploring novel therapeutic strategies aimed at blocking the pathogenic cross talk between neurons and glial cells.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

  • Requena Osete, Jordi
  • Álvarez Palomo, Ana Belén
  • Codina Pascual, M.
  • Delgado-Morales, Raul
  • Moran, Sebastian
  • Esteller, Manel, 1968-
  • Sal, M.
  • Boronat Barado, Anna
  • Consiglio, Antonella
  • Addeleccia Bogle, O.
  • Wolwertang, E.
  • Ovchinnikov, D.
  • Álvarez, Iñaki
  • Jaraquemada, Dolores
  • Mezquita Pla, Jovita
  • Oliva, R.
  • Edel, Michael John
When considering the clinical applications of autologous cell replacement therapy of human iPSC‐derived cells there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC‐derived cells including neural stem cells made from either retroviral, episomal or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC‐derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC‐NSC functions to suppress NF‐KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC‐derived cells to viral infection. The sustained wild type TLR3 and TLR3 isoform over expression is central to understanding the altered immunogenicity of human iPSC‐derived cells calling for screening of human iPSC‐derived cells for TLR3 expression levels before applications.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against alpha-Synuclein-Induced Toxicity

  • Kim, Hanna
  • Calatayud Aristoy, Carles
  • Guha, Sanjib
  • Fernandez-Carasa, Irene
  • Berkowitz, Laura
  • Carballo Carbajal, Iria
  • Ezquerra Trabalón, Mario
  • Fernandez Santiago, Ruben
  • Kapahi, Pankaj
  • Raya Chamorro, Ángel
  • Miranda Vizuete, Antonio
  • Miguel Lizcano, Jose
  • Vila, Miquel
  • Caldwell, Kim A.
  • Caldwell, Guy A.
  • Consiglio, Antonella
  • Dalfo, Esther
Parkinson's disease is associated with intracellular α-synuclein accumulation and ventral midbrain dopaminergic neuronal death in the Substantia Nigra of brain patients. The Rho GTPase pathway, mainly linking surface receptors to the organization of the actin and microtubule cytoskeletons, has been suggested to participate to Parkinson's disease pathogenesis. Nevertheless, its exact contribution remains obscure. To unveil the participation of the Rho GTPase family to the molecular pathogenesis of Parkinson's disease, we first used C elegans to demonstrate the role of the small GTPase RAC1 (ced-10 in the worm) in maintaining dopaminergic function and survival in the presence of alpha-synuclein. In addition, ced-10 mutant worms determined an increase of alpha-synuclein inclusions in comparison to control worms as well as an increase in autophagic vesicles. We then used a human neuroblastoma cells (M17) stably over-expressing alpha-synuclein and found that RAC1 function decreased the amount of amyloidogenic alpha-synuclein. Further, by using dopaminergic neurons derived from patients of familial LRRK2-Parkinson's disease we report that human RAC1 activity is essential in the regulation of dopaminergic cell death, alpha-synuclein accumulation, participates in neurite arborization and modulates autophagy. Thus, we determined for the first time that RAC1/ced-10 participates in Parkinson's disease associated pathogenesis and established RAC1/ced-10 as a new candidate for further investigation of Parkinson's disease associated mechanisms, mainly focused on dopaminergic function and survival against α-synuclein-induced toxicity.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons

  • Calatayud, Carles
  • Carola, Giulia
  • Fernández-Carasa, Irene
  • Valtorta, Marco
  • Jiménez-Delgado, Senda
  • Díaz, Mònica
  • Soriano-Fradera, Jordi
  • Cappelletti, Graziella
  • García-Sancho, Javier
  • Raya, Ángel
  • Consiglio, Antonella
Patient-specific induced pluripotent stem cells (iPSCs) are a powerful tool to investigate the molecular mechanisms underlying Parkinson’s disease (PD), and might provide novel platforms for systematic drug screening. Several strategies have been developed to generate iPSC-derived tyrosine hydroxylase (TH)-positive dopaminergic neurons (DAn), the clinically relevant cell type in PD; however, they often result in mixed neuronal cultures containing only a small proportion of TH-positive DAn. To overcome this limitation, we used CRISPR/Cas9-based editing to generate a human iPSC line expressing a fluorescent protein (mOrange) knocked-in at the last exon of the TH locus. After differentiation of the TH-mOrange reporter iPSC line, we confirmed that mOrange expression faithfully mimicked endogenous TH expression in iPSC-derived DAn. We also employed calcium imaging techniques to determine the intrinsic functional differences between dopaminergic and non-dopaminergic ventral midbrain neurons. Crucially, the brightness of mOrange allowed direct visualization of TH-expressing cells in heterogeneous cultures, and enabled us to isolate live mOrange-positive cells through fluorescence-activated cell sorting, for further differentiation. This technique, coupled to refined imaging and data processing tools, could advance the investigation of PD pathogenesis and might offer a platform to test potential new therapeutics for PD and other neurodegenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the European Union’s Horizon 2020 Program (MESOBRAIN project; grant agreement No 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (SAF2015-69706-R; BFU2017-83066-P; and BFU2016-80870-P), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0003 and RD16/0011/0024; PIE12/00061), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. C.C. is supported by the PD-HUMMODEL European Research Council (ERC)- Ideas PhD fellowship. G.C. is partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration

  • Carola, G.
  • Malagarriga, D.
  • Calatayud, Carles
  • Pons-Espinal, M.
  • Blasco-Agell, Lucas
  • Richaud-Patin, Y.
  • Fernández-Carasa, Irene
  • Baruffi, V.
  • Beltramone, S.
  • Molina, E.
  • Dell’Era, P.
  • Toledo-Aral, Juan José
  • Tolosa, Eduard
  • Muotri , A. R.
  • García Ojalvo, J.
  • Soriano, J.
  • Raya, A.
  • Consiglio, Antonella
A deeper understanding of early disease mechanisms occurring in Parkinson’s disease (PD) is needed to reveal restorative targets. Here we report that human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (DAn) obtained from healthy individuals or patients harboring LRRK2 PD-causing mutation can create highly complex networks with evident signs of functional maturation over time. Compared to control neuronal networks, LRRK2 PD patients’ networks displayed an elevated bursting behavior, in the absence of neurodegeneration. By combining functional calcium imaging, biophysical modeling, and DAn-lineage tracing, we found a decrease in DAn neurite density that triggered overall functional alterations in PD neuronal networks. Our data implicate early dysfunction as a prime focus that may contribute to the initiation of downstream degenerative pathways preceding DAn loss in PD, highlighting a potential window of opportunity for pre-symptomatic assessment of chronic degenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the MESOBRAIN project from the European Union’s Horizon 2020 research and innovation (grant agreement No. 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100, FIS2016-78507-C2-2-P, PID2019-108842GB-C21) the Spanish Ministry of Economy and Competitiveness-MINECO/AEI/FEDER, UE (BFU2016-80870-P) and the Spanish Ministry of Economy and Competitiveness- AEI/10.13039/501100011033 (PID2019-108792GB-I00), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024 and RD16/0011/0025), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. M.P.E. was partially supported by a Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia (2017 BP 00133). L.B. is the recipient of a pre-doctoral fellowship FPI (BES-2017-080579) from the Spanish Ministry of Economy and Competitiveness (MINECO). G.C. was partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

  • Requena Osete, Jordi
  • Álvarez Palomo, Ana Belén
  • Codina Pascual, M.
  • Delgado-Morales, Raul
  • Moran, Sebastian
  • Esteller, Manel
  • Sal, M.
  • Boronat Barado, Anna
  • Consiglio, Antonella
  • Addeleccia Bogle, O.
  • Wolwertang, E.
  • Ovchinnikov, D.
  • Álvarez, Iñaki
  • Jaraquemada, Dolores
  • Mezquita Pla, Jovita
  • Oliva, R.
  • Edel, Michael John
When considering the clinical applications of autologous cell replacement therapy of human iPSC‐derived cells there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC‐derived cells including neural stem cells made from either retroviral, episomal or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC‐derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC‐NSC functions to suppress NF‐KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC‐derived cells to viral infection. The sustained wild type TLR3 and TLR3 isoform over expression is central to understanding the altered immunogenicity of human iPSC‐derived cells calling for screening of human iPSC‐derived cells for TLR3 expression levels before applications.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Long-term labeling of hippocampal neural stem cells by a lentiviral vector

  • Suh, Hoonkyo
  • Zhou, Qi-Gang
  • Fernandez-Carasa, Irene
  • Clemenson Jr., Gregory D.
  • Pons-Espinal, Meritxell
  • Jeoung Ro, Eun
  • Marti, Mercè
  • Raya Chamorro, Ángel
  • Gage, Fred H.
  • Consiglio, Antonella
Using a lentivirus-mediated labeling method, we investigated whether the adult hippocampus retains long-lasting, self-renewing neural stem cells (NSCs). We first showed that a single injection of a lentiviral vector expressing a green fluorescent protein (LV PGK-GFP) into the subgranular zone (SGZ) of the adult hippocampus enabled an efficient, robust, and long-term marking of self-renewing NSCs and their progeny. Interestingly, a subset of labeled cells showed the ability to proliferate multiple times and give rise to Sox2+ cells, clearly suggesting the ability of NSCs to self-renew for an extensive period of time (up to 6 months). In addition, using GFP+ cells isolated from the SGZ of mice that received a LV PGK-GFP injection 3 months earlier, we demonstrated that some GFP+ cells displayed the essential properties of NSCs, such as self-renewal and multipotency. Furthermore, we investigated the plasticity of NSCs in a perforant path transection, which has been shown to induce astrocyte formation in the molecular layer of the hippocampus. Our lentivirus (LV)-mediated labeling study revealed that hippocampal NSCs are not responsible for the burst of astrocyte formation, suggesting that signals released from the injured perforant path did not influence NSC fate determination. Therefore, our studies showed that a gene delivery system using LVs is a unique method to be used for understanding the complex nature of NSCs and may have translational impact in gene therapy by efficiently targeting NSCs.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

  • Fernández-Santiago, Ruben
  • Merkel, Angelika
  • Castellano, Giancarlo
  • Heath, Simon
  • Raya Chamorro, Ángel
  • Tolosa, Eduard
  • Martí, Maria José
  • Consiglio, Antonella
  • Ezquerra, Mario
Background: Parkinson’s disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues., This work was supported by the Fondo de Investigaciones Sanitarias of the Instituto de Salud Carlos III (ISCIII) to M.E. (grant # PI14/00426), the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) to the Movement Disorders Unit of the Neurology Service from the Hospital Clínic de Barcelona to E.T., M.-J.M., R.F.-S., and M.E. (grant # PRI-16-2017). R.F.S. was supported by a Jóvenes Investigadores grant (#SAF2015-73508-JIN) through the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (Plan Estatal de I+D+I 2013–2016) of the Spanish Ministry of Economy and Competitiveness (MINECO), and the Agencia Estatal de Investigación (AEI), which is cofunded by FEDER (AEI/FEDER/UE). Other funding included the grants BFU2013-49157-P, BFU2016-80870-P, and the European Research Council (ERC) 2012-StG (311736- PD-HUMMODEL) to A.C; ISCIII/FEDER (RD16/0011/0024) and Generalitat de Catalunya (iPS4BioMed SGR 2017–2019) to A.R.; and ISCIII/FEDER (PIE14/00061) to A.R.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells

  • Pons-Espinal, Meritxell
  • Blasco Agell, Lucas
  • Consiglio, Antonella
Parkinson's disease (PD) is an incurable age-linked neurodegenerative disease with characteristic movement impairments that are caused by the progressive loss of dopamine-containing neurons (DAn) within the substantia nigra pars compacta. It has been suggested that misfolded protein aggregates together with neuroinfammation and glial reactivity, may impact nerve cell function, leading to neurodegeneration and diseases, such as PD. However, not many studies have been able to examine the role of human glial cells in the pathogenesis of PD. With the advent of induced pluripotent stem cell (iPSC) technology, it is now possible to reprogram human somatic cells to pluripotency and to generate viable human patient-specifc DA neurons and glial cells, providing a tremendous opportunity for dissecting cellular and molecular pathological mechanisms occurring at early stages of PD. This reviews will report on recent work using human iPSC and 3D brain organoid models showing that iPSC technology can be used to recapitulate PD-relevant disease-associated phenotypes, including protein aggregation, cell death or loss of neurite complexity and defcient autophagic vacuoles clearance and focus on the recent co-culture systems that are revealing new insights into the complex interactions that occur between diferent brain cell types during neurodegeneration. Consequently, such advances are the key to improve our understanding of PD pathology and generate potential targets for new therapies aimed at curing PD patients.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Whole-genome DNA hyper-methylation in iPSC-derived dopaminergic neurons from Parkinson's disease patients

  • Fernández Santiago, Rubén
  • Merkel, Angelika
  • Castellano, Giancarlo
  • Heath, Simon
  • Raya Chamorro, Ángel
  • Tolosa, Eduardo
  • Martí Domènech, Ma. Josep
  • Consiglio, Antonella
  • Ezquerra Trabalón, Mario
Background: Parkinson's disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn). Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene regulatory regions. Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient, one monogenic LRRK2-associated PD patient (L2PD), and one control. Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread across the genome in both sPD and L2PD and mostly affected intergenic regions. Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory study are to be validated in further studies analyzing other PD cell models and patient tissues.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson's disease

  • Domenico, Angelique Di
  • Carola, Giulia
  • Calatayud Aristoy, Carles
  • Pons-Espinal, Meritxell
  • Muñoz, Juan Pablo
  • Richaud-Patin, Yvonne
  • Fernandez-Carasa, Irene
  • Gut, Marta
  • Faella, Armida
  • Parameswaran, Janani
  • Soriano i Fradera, Jordi
  • Ferrer, Isidro (Ferrer Abizanda)
  • Tolosa, Eduardo
  • Zorzano Olarte, Antonio
  • Cuervo, Ana Maria
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
Parkinson's disease (PD) is associated with the degeneration of ventral midbrain dopaminergic neurons (vmDAns) and the accumulation of toxic α-synuclein. A non-cell-autonomous contribution, in particular of astrocytes, during PD pathogenesis has been suggested by observational studies, but remains to be experimentally tested. Here, we generated induced pluripotent stem cell-derived astrocytes and neurons from familial mutant LRRK2 G2019S PD patients and healthy individuals. Upon co-culture on top of PD astrocytes, control vmDAns displayed morphological signs of neurodegeneration and abnormal, astrocyte-derived α-synuclein accumulation. Conversely, control astrocytes partially prevented the appearance of disease-related phenotypes in PD vmDAns. We additionally identified dysfunctional chaperone-mediated autophagy (CMA), impaired macroautophagy, and progressive α-synuclein accumulation in PD astrocytes. Finally, chemical enhancement of CMA protected PD astrocytes and vmDAns via the clearance of α-synuclein accumulation. Our findings unveil a crucial non-cell-autonomous contribution of astrocytes during PD pathogenesis, and open the path to exploring novel therapeutic strategies aimed at blocking the pathogenic cross talk between neurons and glial cells.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neural cells

  • Bayó Puxan, Neus
  • Terrasso, Ana Paula
  • Creyssels, Sophie
  • Simão, Daniel
  • Begon Pescia, Christina
  • Lavigne, Marina
  • Salinas, Sara
  • Bernex, Florence
  • Bosch, Assumpció
  • Kalatzis, Vasiliki
  • Levade, Thierry
  • Cuervo, Ana María
  • Lory, Philippe
  • Consiglio, Antonella
  • Brito, Catarina
Mucopolysaccharidosis type VII (MPS VII) is a lysosomal storage disease caused by deficient β-glucuronidase (β-gluc) activity. Significantly reduced β-gluc activity leads to accumulation of glycosaminoglycans (GAGs) in many tissues, including the brain. Numerous combinations of mutations in GUSB (the gene that codes for β-gluc) cause a range of neurological features that make disease prognosis and treatment challenging. Currently, there is little understanding of the molecular basis for MPS VII brain anomalies. To identify a neuronal phenotype that could be used to complement genetic analyses, we generated two iPSC clones derived from skin fibroblasts of an MPS VII patient. We found that MPS VII neurons exhibited reduced β-gluc activity and showed previously established disease-associated phenotypes, including GAGs accumulation, expanded endocytic compartments, accumulation of lipofuscin granules, more autophagosomes, and altered lysosome function. Addition of recombinant β-gluc to MPS VII neurons, which mimics enzyme replacement therapy, restored disease-associated phenotypes to levels similar to the healthy control. MPS VII neural cells cultured as 3D neurospheroids showed upregulated GFAP gene expression, which was associated with astrocyte reactivity, and downregulation of GABAergic neuron markers. Spontaneous calcium imaging analysis of MPS VII neurospheroids showed reduced neuronal activity and altered network connectivity in patient-derived neurospheroids compared to a healthy control. These results demonstrate the interplay between reduced β-gluc activity, GAG accumulation and alterations in neuronal activity, and provide a human experimental model for elucidating the bases of MPS VII-associated cognitive defects.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against alpha-Synuclein-Induced Toxicity

  • Kim, Hanna
  • Calatayud Aristoy, Carles
  • Guha, Sanjib
  • Fernandez-Carasa, Irene
  • Berkowitz, Laura
  • Carballo Carbajal, Iria
  • Ezquerra Trabalón, Mario
  • Fernandez Santiago, Ruben
  • Kapahi, Pankaj
  • Raya Chamorro, Ángel
  • Miranda Vizuete, Antonio
  • Miguel Lizcano, Jose
  • Vila, Miquel
  • Caldwell, Kim A.
  • Caldwell, Guy A.
  • Consiglio, Antonella
  • Dalfo, Esther
Parkinson's disease is associated with intracellular α-synuclein accumulation and ventral midbrain dopaminergic neuronal death in the Substantia Nigra of brain patients. The Rho GTPase pathway, mainly linking surface receptors to the organization of the actin and microtubule cytoskeletons, has been suggested to participate to Parkinson's disease pathogenesis. Nevertheless, its exact contribution remains obscure. To unveil the participation of the Rho GTPase family to the molecular pathogenesis of Parkinson's disease, we first used C elegans to demonstrate the role of the small GTPase RAC1 (ced-10 in the worm) in maintaining dopaminergic function and survival in the presence of alpha-synuclein. In addition, ced-10 mutant worms determined an increase of alpha-synuclein inclusions in comparison to control worms as well as an increase in autophagic vesicles. We then used a human neuroblastoma cells (M17) stably over-expressing alpha-synuclein and found that RAC1 function decreased the amount of amyloidogenic alpha-synuclein. Further, by using dopaminergic neurons derived from patients of familial LRRK2-Parkinson's disease we report that human RAC1 activity is essential in the regulation of dopaminergic cell death, alpha-synuclein accumulation, participates in neurite arborization and modulates autophagy. Thus, we determined for the first time that RAC1/ced-10 participates in Parkinson's disease associated pathogenesis and established RAC1/ced-10 as a new candidate for further investigation of Parkinson's disease associated mechanisms, mainly focused on dopaminergic function and survival against α-synuclein-induced toxicity.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

iPS cell cultures from a Gerstmann-Straussler-Scheinker patient with the Y218N PRNP mutation recapitulate tau pathology

  • Matamoros i Anglès, Andreu
  • Mayela Gayosso, Lucia
  • Richaud-Patin, Yvonne
  • Domenico, Angelique Di
  • Vergara Paños, Cristina
  • Hervera Abad, Arnau
  • Sousa, Amaia
  • Fernández Borges, Natalia
  • Consiglio, Antonella
  • Gavín Marín, Rosalina
  • López de Maturana, Rakel
  • Ferrer, Isidro (Ferrer Abizanda)
  • López de Munain, Adolfo
  • Raya Chamorro, Ángel
  • Castilla, Joaquín
  • Sanchez-Pernaute, Rosario
  • Río Fernández, José Antonio del
Gerstmann-Straussler-Scheinker (GSS) syndrome is a fatal autosomal dominant neurodegenerative prionopathy clinically characterized by ataxia, spastic paraparesis, extrapyramidal signs and dementia. In some GSS familiar cases carrying point mutations in the PRNP gene, patients also showed comorbid tauopathy leading to mixed pathologies. In this study we developed an induced pluripotent stem (iPS) cell model derived from fibroblasts of a GSS patient harboring the Y218N PRNP mutation, as well as an age-matched healthy control. This particular PRNP mutation is unique with very few described cases. One of the cases presented neurofibrillary degeneration with relevant Tau hyperphosphorylation. Y218N iPS-derived cultures showed relevant astrogliosis, increased phospho-Tau, altered microtubule-associated transport and cell death. However, they failed to generate proteinase K-resistant prion. In this study we set out to test, for the first time, whether iPS cell-derived neurons could be used to investigate the appearance of disease-related phenotypes (i.e, tauopathy) identified in the GSS patient.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons

  • Calatayud Aristoy, Carles
  • Carola, Giulia
  • Fernandez-Carasa, Irene
  • Valtorta, Marco
  • Jiménez-Delgado, Senda
  • Díaz, Mònica
  • Soriano i Fradera, Jordi
  • Cappelletti, Graziella
  • García-Sancho, Javier
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
Patient-specific induced pluripotent stem cells (iPSCs) are a powerful tool to investigate the molecular mechanisms underlying Parkinson's disease (PD), and might provide novel platforms for systematic drug screening. Several strategies have been developed to generate iPSC-derived tyrosine hydroxylase (TH)-positive dopaminergic neurons (DAn), the clinically relevant cell type in PD; however, they often result in mixed neuronal cultures containing only a small proportion of TH-positive DAn. To overcome this limitation, we used CRISPR/Cas9-based editing to generate a human iPSC line expressing a fluorescent protein (mOrange) knocked-in at the last exon of the TH locus. After differentiation of the TH-mOrange reporter iPSC line, we confirmed that mOrange expression faithfully mimicked endogenous TH expression in iPSC-derived DAn. We also employed calcium imaging techniques to determine the intrinsic functional differences between dopaminergic and non-dopaminergic ventral midbrain neurons. Crucially, the brightness of mOrange allowed direct visualization of TH-expressing cells in heterogeneous cultures, and enabled us to isolate live mOrange-positive cells through fluorescence-activated cell sorting, for further differentiation. This technique, coupled to refined imaging and data processing tools, could advance the investigation of PD pathogenesis and might offer a platform to test potential new therapeutics for PD and other neurodegenerative diseases.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons

  • Ferrer Lorente, Raquel
  • Lozano Cruz, Tania
  • Fernández Carasa, Irene
  • Miłowska, Katarzyna
  • Mata, Francisco Javier de la
  • Bryszewska, Maria
  • Consiglio, Antonella
  • Ortega, Paula
  • Gómez, Rafael
  • Raya Chamorro, Ángel
Accumulation of misfolded α-synuclein (α-syn) is a hallmark of Parkinson's disease (PD) thought to play important roles in the pathophysiology of the disease. Dendritic systems, able to modulate the folding of proteins, have emerged as promising new therapeutic strategies for PD treatment. Dendrimers have been shown to be effective at inhibiting α-syn aggregation in cell-free systems and in cell lines. Here, we set out to investigate the effects of dendrimers on endogenous α-syn accumulation in disease-relevant cell types from PD patients. For this purpose, we chose cationic carbosilane dendrimers of bow-tie topology based on their performance at inhibiting α-syn aggregation in vitro. Dopamine neurons were differentiated from induced pluripotent stem cell (iPSC) lines generated from PD patients carrying the LRRK2G2019S mutation, which reportedly display abnormal accumulation of α-syn, and from healthy individuals as controls. Treatment of PD dopamine neurons with non-cytotoxic concentrations of dendrimers was effective at preventing abnormal accumulation and aggregation of α-syn. Our results in a genuinely human experimental model of PD highlight the therapeutic potential of dendritic systems and open the way to developing safe and efficient therapies for delaying or even halting PD progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The small GTPase RAC1/CED-10 is essential in maintaining dopaminergic neuron function and survival against α-synuclein-induced toxicity

  • Kim, Hanna
  • Calatayud, Carles|||0000-0003-0032-4198
  • Guha, Sanjib
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Berkowitz, Laura
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Kapahi, Pankaj
  • Raya, Ángel|||0000-0003-2189-9775
  • Miranda Vizuete, Antonio
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Caldwell, Kim A.
  • Caldwell, Guy A.
  • Consiglio, Antonella
  • Dalfo, Esther|||0000-0003-4677-8515
Parkinson's disease is associated with intracellular α-synuclein accumulation and ventral midbrain dopaminergic neuronal death in the Substantia Nigra of brain patients. The Rho GTPase pathway, mainly linking surface receptors to the organization of the actin and microtubule cytoskeletons, has been suggested to participate to Parkinson's disease pathogenesis. Nevertheless, its exact contribution remains obscure. To unveil the participation of the Rho GTPase family to the molecular pathogenesis of Parkinson's disease, we first used C elegans to demonstrate the role of the small GTPase RAC1 (ced-10 in the worm) in maintaining dopaminergic function and survival in the presence of alpha-synuclein. In addition, ced-10 mutant worms determined an increase of alpha-synuclein inclusions in comparison to control worms as well as an increase in autophagic vesicles. We then used a human neuroblastoma cells (M17) stably over-expressing alpha-synuclein and found that RAC1 function decreased the amount of amyloidogenic alpha-synuclein. Further, by using dopaminergic neurons derived from patients of familial LRRK2-Parkinson's disease we report that human RAC1 activity is essential in the regulation of dopaminergic cell death, alpha-synuclein.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Global proteomic and methylome analysis in human induced pluripotent stem cells reveals overexpression of a human TLR3 affecting proper innate immune response signaling

  • Requena, Jordi
  • Álvarez Palomo, Belén|||0000-0002-3894-044X
  • Codina, Montserrat|||0000-0001-5591-8095
  • Delgado Morales, Raúl|||0000-0002-8538-4087
  • Moran, S.|||0000-0003-4192-8983
  • Esteller, M.|||0000-0003-4490-6093
  • Sal, Martí
  • Juan, Manel|||0000-0002-3064-1648
  • Boronat Barado, Anna
  • Consiglio, Antonella
  • Bogle, Orleigh Addeleccia
  • Wolvetang, Ernst
  • Ovchinnikov, Dmitry
  • Álvarez Pérez, Iñaki|||0000-0001-9484-0868
  • Jaraquemada, Dolores|||0000-0003-3328-740X
  • Mezquita Pla, Jovita
  • Oliva Virgili, Rafael|||0000-0003-4876-2410
  • Edel, Michael J.|||0000-0002-5619-8680
When considering the clinical applications of autologous cell replacement therapy of human induced pluripotent stem cells (iPSC)-derived cells, there is a clear need to better understand what the immune response will be before we embark on extensive clinical trials to treat or model human disease. We performed a detailed assessment comparing human fibroblast cell lines (termed F1) reprogrammed into human iPSC and subsequently differentiated back to fibroblast cells (termed F2) or other human iPSC-derived cells including neural stem cells (NSC) made from either retroviral, episomal, or synthetic mRNA cell reprogramming methods. Global proteomic analysis reveals the main differences in signal transduction and immune cell protein expression between F1 and F2 cells, implicating wild type (WT) toll like receptor protein 3 (TLR3). Furthermore, global methylome analysis identified an isoform of the human TLR3 gene that is not epigenetically reset correctly upon differentiation to F2 cells resulting in a hypomethylated transcription start site in the TLR3 isoform promoter and overexpression in most human iPSC-derived cells not seen in normal human tissue. The human TLR3 isoform in human iPSC-NSC functions to suppress NF-KB p65 signaling pathway in response to virus (Poly IC), suggesting suppressed immunity of iPSC-derived cells to viral infection. The sustained WT TLR3 and TLR3 isoform overexpression is central to understanding the altered immunogenicity of human iPSC-derived cells calling for screening of human iPSC-derived cells for TLR3 expression levels before applications. Stem Cells 2019;37:476-488.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neurons

  • Bayó-Puxan, Neus|||0000-0001-9909-1499
  • Terrasso, Ana Paula
  • Creyssels, Sophie
  • Simão, Daniel
  • Begon-Pescia, Christina
  • Lavigne, Marina
  • Salinas, Sara
  • Bernex, Florence
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Kalatzis, Vasiliki|||0000-0002-9626-8807
  • Levade, Thierry
  • Cuervo, Ana Maria|||0000-0002-0771-700X
  • Lory, Philippe
  • Consiglio, Antonella|||0000-0001-9890-0274
  • Brito, Catarina
  • Kremer, Eric J.
Mucopolysaccharidosis type VII (MPS VII) is a lysosomal storage disease caused by deficient β-glucuronidase (β-gluc) activity. Significantly reduced β-gluc activity leads to accumulation of glycosaminoglycans (GAGs) in many tissues, including the brain. Numerous combinations of mutations in GUSB (the gene that codes for β-gluc) cause a range of neurological features that make disease prognosis and treatment challenging. Currently, there is little understanding of the molecular basis for MPS VII brain anomalies. To identify a neuronal phenotype that could be used to complement genetic analyses, we generated two iPSC clones derived from skin fibroblasts of an MPS VII patient. We found that MPS VII neurons exhibited reduced β-gluc activity and showed previously established disease-associated phenotypes, including GAGs accumulation, expanded endocytic compartments, accumulation of lipofuscin granules, more autophagosomes, and altered lysosome function. Addition of recombinant β-gluc to MPS VII neurons, which mimics enzyme replacement therapy, restored disease-associated phenotypes to levels similar to the healthy control. MPS VII neural cells cultured as 3D neurospheroids showed upregulated GFAP gene expression, which was associated with astrocyte reactivity, and downregulation of GABAergic neuron markers. Spontaneous calcium imaging analysis of MPS VII neurospheroids showed reduced neuronal activity and altered network connectivity in patient-derived neurospheroids compared to a healthy control. These results demonstrate the interplay between reduced β-gluc activity, GAG accumulation and alterations in neuronal activity, and provide a human experimental model for elucidating the bases of MPS VII-associated cognitive defects.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase, Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model

  • Jung-KC, Kunwar|||0000-0002-6745-7318
  • Tristán Noguero, Alba|||0000-0002-0170-9762
  • Altankhuyag, Altanchimeg
  • Piñol Belenguer, David|||0000-0001-7490-5054
  • Prestegård, Karina S.|||0000-0003-3706-6751
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Colini Baldeschi, Arianna|||0000-0002-8638-3705
  • Sigatulina Bondarenko, Maria
  • García-Cazorla, Angels|||0000-0001-9853-688X
  • Consiglio, Antonella
  • Martinez, Aurora|||0000-0003-1643-6506
Proteostatic regulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is crucial for maintaining proper brain neurotransmitter homeostasis. Variants of the TH gene are associated with tyrosine hydroxylase deficiency (THD), a rare disorder with a wide phenotypic spectrum and variable response to treatment, which affects protein stability and may lead to accelerated degradation, loss of TH function and catecholamine deficiency. In this study, we investigated the effects of the TH cofactor tetrahydrobiopterin (BH) on the stability of TH in isolated protein and in DAn- differentiated from iPSCs from a human healthy subject, as well as from THD patients with the R233H variant in homozygosity (THDA) and R328W and T399M variants in heterozygosity (THDB). We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells. To translate this in vitro effect, we treated with BH a knock-in THD mouse model with Th variant corresponding to R233H in patients. Importantly, treatment with BH significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy). In conclusion, our study demonstrates the stabilizing effects of BH on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes. These findings highlight the therapeutic potential of BH as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Cationic Carbosilane Dendrimers Prevent Abnormal alfa-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons

  • Ortega Lopez, Paula|||0000-0003-0377-5429
  • Mata de la Mata, Francisco Javier de la|||0000-0003-0418-3935
  • Gómez Ramírez, Rafael|||0000-0001-6448-2414
  • Raya, Ángel
  • Ferrer Lorente, Raquel
  • Lozano de la Cruz, Tania
  • Fernández Carasa, Irene
  • Bryszewska, Maria
  • Milowska, Katarzyna
  • Consiglio, Antonella
Accumulation of misfolded alpha-synuclein (alpha-syn) is a hallmark of Parkinson's disease (PD) thought to play important roles in the pathophysiology of the disease. Dendritic systems, able to modulate the folding of proteins, have emerged as promising new therapeutic strategies for PD treatment. Dendrimers have been shown to be effective at inhibiting alpha-syn aggregation in cell-free systems and in cell lines. Here, we set out to investigate the effects of dendrimers on endogenous alpha-syn accumulation in disease-relevant cell types from PD patients. For this purpose, we chose cationic carbosilane dendrimers of bow-tie topology based on their performance at inhibiting alpha-syn aggregation in vitro. Dopamine neurons were differentiated from induced pluripotent stem cell (iPSC) lines generated from PD patients carrying the LRRK2(G20195) mutation, which reportedly display abnormal accumulation of alpha-syn, and from healthy individuals as controls. Treatment of PD dopamine neurons with non-cytotoxic concentrations of dendrimers was effective at preventing abnormal accumulation and aggregation of alpha-syn. Our results in a genuinely human experimental model of PD highlight the therapeutic potential of dendritic systems and open the way to developing safe and efficient therapies for delaying or even halting PD progression., European Research Council, Polish National Agency for Academic Exchange, Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Instituto de Salud Carlos III, Agencia de Gestión de Ayudas Universitarias y de Investigación, Comunidad Autónoma de Madrid, Generalitat de Catalunya